Surge in obesity drugs like Ozempic have pummeled big food stocks. Is it time to eat them up?

Mr. Market is still having major digestive issues with the stocks of the world's largest food and beverage companies.) have shed an average of 13.5% in the past six months, according to numbers crunched by Yahoo Finance. The Dow Jones Industrial Average and S&P 500 are each down about 1% over the same time span.

"Although only around 1% of U.S. adults have current prescriptions for Ozempic, Wegovy and Mounjaro, the recent acceleration in demand for these drugs for weight loss is raising profound questions about what this could mean for the future of healthcare and food and beverage consumption," pointed out veteran Bernstein analyst Alexia Howard in an exhaustive new piece of research this week.

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Ozempic Risk, Higher Rates Fuel Short Bets on Restaurant Stocks - BNN BloombergShort sellers have boosted their bets against restaurant stocks in the past month, with concerns swirling that higher interest rates will pinch consumers’ wallets and weight-loss drugs will impact their behavior.
Fonte: BNNBloomberg - 🏆 83. / 50 Consulte Mais informação »